Caring for Canada’s children

Life in child welfare care, as you stated in your editorial “Every child deserves a home,” is a difficult experience for every child, even when the system works well. In our experience, children and youth yearn for not just a placement but a “home.” For many children and youth, this “home” can be found through adoption. For other children and youth, the system can work differently to provide homes when adoption is not the alternative chosen by the young person.

Rules and regulations that impede permanency in placement can be altered. In Ontario, a youth must leave a foster home by 18 years of age because the per diem to foster parents ends. This occurs even when the foster parent and youth wish for another arrangement. In Ontario, while attention is said to be given to Kinship Care placements, little or no support is given to those placements. Youth have said to us, “you can choose your friends and you can choose your family.” This support must be given to young people in the care of the child welfare system to choose and build their families.

Irwin Elman
Provincial advocate for children and youth, Province of Ontario, Toronto

REFERENCE

For the full letter, go to: www.cmaj.ca/cgi/eletters/181/12/254628

Why didn’t it work?

Re: “The Enhancing Secondary Prevention in Coronary Artery Disease trial.” As a family physician, two possible explanations come to mind for these surprisingly ‘negative’ results. First, since the patients had elective catheterizations, the primary-care providers may have assumed ongoing follow-up with a cardiologist. Second, with over 80% on a statin, it is possible that these patients had other comorbidities judged to be of higher priority than reaching a maximal statin dose. I agree with the authors that simple interventions are worth testing and I wonder if the team may have benefited from adding a qualitative component to this intervention. This may have allowed the team to identify barriers to prescribing for coronary artery disease and to potentially adjust the intervention accordingly. The result could have been a perception that the intervention was ‘from the ground up,’ leading to greater buy-in. Another option may be to conduct interviews with the participating physicians to learn more about why it did not work as expected.

Noah M. Ivers MD
Women’s College Hospital, University of Toronto, Toronto, Ont.

REFERENCE

For the full letter, go to: www.cmaj.ca/cgi/eletters/181/12/259747

Where are the drugs from?

The oxycodone problem is significant, especially in small northern communities, where a little bit of addiction goes a long way in disabling a whole community. Clinicians in our region are aware of the devastation opioid addiction can cause and are careful with prescribing. The authors of “Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.” note that many people with fatal overdoses have seen a doctor for a prescription in a preceding time frame. What is not clear is whether that is their main source of narcotics. Do the authors have any information on nonprescribed narcotic abuse/access? Is the problem that individual prescriptions are being misused or the access to illicit bulk narcotic drug trade?

Len Kelly MD
Northern Ontario School of Medicine
Sioux Lookout, Ont.

REFERENCE

For the full letter, go to: www.cmaj.ca/cgi/eletters/181/12/254302

High cost, dubious benefit

Re: “Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.” In medical school, I was given the textbook Managing Pain: The Canadian Healthcare Professional’s Guide. The book recommends prescribing oxycodone over morphine and endorses continuous release opioids because of a “lower abuse potential.” The production costs of the manual were paid for by the manufacturer of OxyContin (oxycodone).

Even though opioid misuse is a very complicated issue, some simple changes may be helpful. Eighty milligram oxycodone pills remain on public formulary in Ontario despite the fact that this dose is not supported by current pain management guidelines. The Committee to Evaluate Drugs recently recommended that 5 mg controlled-release oxycodone pills not be added to the formulary in Ontario, noting the cost and that “oxycodone has not been demonstrated to be therapeutically superior to morphine or other opioid analgesics.” Similar reasoning might lead them to remove oxycodone from the public formulary altogether. The millions of dollars saved could be spent on safer pain management modalities.

The unpleasantness of denying patients opioids sometimes makes it difficult for me to remember that doing so is safe and often appropriate. Indeed, while there is virtually no evidence that